Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-16
2011-08-16
Huff, Sheela J (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391900
Reexamination Certificate
active
07999083
ABSTRACT:
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
REFERENCES:
patent: 4359457 (1982-11-01), Neville et al.
patent: 5112954 (1992-05-01), Abrams et al.
patent: 5708146 (1998-01-01), Willner et al.
patent: 5824701 (1998-10-01), Greenwald et al.
patent: 6156754 (2000-12-01), Lerchen et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6716821 (2004-04-01), Zhao et al.
patent: 7122636 (2006-10-01), Hsei et al.
patent: 7238785 (2007-07-01), Govindan et al.
patent: 7312318 (2007-12-01), Hansen et al.
patent: 2001/0034363 (2001-10-01), Li et al.
patent: 2003/0133972 (2003-07-01), Danthi et al.
patent: 2004/0001838 (2004-01-01), Zhao et al.
patent: 2006/0142506 (2006-06-01), Breitenkamp et al.
patent: 2008/0166363 (2008-07-01), Govindan et al.
patent: 0253202 (1988-01-01), None
patent: 0306943 (1989-03-01), None
patent: 0076551 (2000-12-01), None
patent: 0124763 (2001-04-01), None
patent: 2004054622 (2004-07-01), None
patent: WO 2004054622 (2004-07-01), None
Walker et al. (Bioorganic and Medicinal Chemistry Letters 2002; 12: 217-219).
Hatzakis et al. (Chem. Communication, 2006; 2012-2014.
Suzawa et al. (Bioorganic & Medicinal Chemistry 2000; 8: 2175-2184).
Suzuwa et al. (J. Controlled Release 2002; 79: 229-242).
Reddy et al., “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4”, J. Immunol. 164:1925-1933 (2000).
International Search Report for PCT/US09/66371, filed Dec. 2, 2009, date of mailing Feb. 12, 2010.
Bennouna et al., “Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer” Int. J. Clin. Oncol. (2002) 7:236-244.
Cao et al., “Bispecific Antibodies as Novel Bioconjugates” Bioconj. Chem. Nov.-Dec. 1998;9(6):635-44.
Chari et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs” Cancer Res. Jan. 1, 1992;52(1):127-31.
Gueritte-Voegelein et al., “Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity” J. Med. Chem. 1991, 34, 992-998.
Guillemard et al., “Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility, and Tumor Target Selectivity” Cancer Res. 61, 694-699, Jan. 15, 2001.
Hatzakis et al., “Synthesis and single enzyme activity of a clicked lipase-BSA hetero-dimer” Chem. Commun., 2006, 2012-2014.
Heindel et al., “A Novel Heterobifunctional Linker for Formyl to Thiol Coupling” Bioconjugate Chem. 1991, 2, 427-430.
Huang et al., “The Rana catesbeiana rcr Gene Encoding a Cytotoxic Ribonuclease” J. Biol. Chem. 273 (11):6395-6401 (1998).
King et al., “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates” Bioconjugate Chem. 1999, 10, 279-288.
Kreitman et al., “Pseudomonas Exotoxin-based Immunotoxins Containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphoma in Mice” Cancer Res. 53, 819-825, Feb. 15, 1993.
Miller et al., “Development of Taxoids with Enhanced Toxicity and Solubility” Poster Presentation, 224th ACS Nat. Meeting, Aug. 18-22, 2002, Boston, MA.
Moon et al., “Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy” J. Med. Chem. 2008, 51, 6916-6926.
Newton et al., “Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma” Blood, 97(2):528-35 (2001).
Perez et al., “Inhibition by the anti-mitotic drug doxorubicin of platelet-activating-factor-induced late eosinophil accumulation in rats” Eur. J. Pharmacol. Sep. 4, 1998;356(2-3):239-43.
Rowlinson-Busza et al., “Targeted delivery of biologic and other antineoplastic agents” Curr. Opin. Oncol. Dec. 1992;4(6):1142-1148.
Shih et al., “The Processing and Fate of Antibodies and Their Radiolabels Bound to the Surface of Tumor Cells In Vitro: A Comparison of Nine Radiolabels” J. Nucl. Med. 1994; 35:899-908.
Suzawa et al., “Synthesis of a Novel Duocarmycin Derivative DU-257 and its Application to Immunoconjugate Using Poly(ethylene glycol)-dipeptidyl Linker Capable of Tumor Specific Activation” Bioorg. Med. Chem. 8(8):2175-84 (2000).
Suzawa et al., “Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker” J. Control. Release 79:229-242 (2002).
Trail et al., “Carcinoma Reactive Doxorubicin (DOX) Conjugates: Comparison of BR64-DOX Conjugates Prepared With Disulfide or Thioether Linkers”, Proc. Amer. Assoc. Cancer Res., vol. 34, Mar. 1993, #2858, p. 479.
Walker et al., “Synthesis of an Immunoconjugate of Camptothecin” Bioorg. Med. Chem. Lett. 12(2):217-219 (2002).
Goldenberg David M.
Govindan Serengulam V.
Moon Sung-Ju
Huff Sheela J
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Immunoconjugates with an intracellularly-cleavable linkage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoconjugates with an intracellularly-cleavable linkage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoconjugates with an intracellularly-cleavable linkage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707780